Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype

Otto, Ferdinand; Moser, Tobias; Feige, Julia; Seiberl, Michael; Bieler, Lara; Sellner, Johann

doi:10.1016/j.msard.2020.102108

Cited by 1 publication

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jarius et al 13 also found no change in ARR in 16 patients who received MS treatment. We did come across one report of disease stabilization in a patient with an MS phenotype and detectable MOG‐IgG following alemtuzumab, but the antibodies were detected with a non–IgG‐specific secondary antibody so false positivity due to IgM cannot be excluded 1,85 …”

Section: Maintenance Therapiesmentioning

confidence: 99%

“…We did come across one report of disease stabilization in a patient with an MS phenotype and detectable MOG-IgG following alemtuzumab, but the antibodies were detected with a non-IgGspecific secondary antibody so false positivity due to IgM cannot be excluded. 1,85 Mitoxantone was approved for the management of patients with relapsing-remitting and early secondary progressive MS in 1999. 86 Details regarding dosing, mode of action, and adverse effects can be found in Table 1.…”

Section: Ms Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G–associated disease

Healy

Elhadd

Gibbons

et al. 2021

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disease (MOGAD) is increasingly recognized as a distinct nosological entity from aquaporin‐4 antibody IgG–positive neuromyelitis optica spectrum disorder (AQP4‐IgG NMOSD). The advent of highly specific MOG‐IgG cell‐based diagnostic assays have helped to refine our understanding of the clinical spectrum of MOGAD. To date, treatment approaches have been largely extrapolated from AQP4‐IgG NMOSD experience, but there is growing evidence of distinct differences in treatment response between these conditions. This review summarizes the current status and understanding of acute and chronic treatments for MOGAD. Timing and duration of treatment, pregnancy, and emerging therapies are also discussed.

show abstract

Section: Maintenance Therapiesmentioning

confidence: 99%